AstraZeneca’s breast cancer pill camizestrant (Etcamah) failed to improve progression-free survival in a late-stage trial when added to standard therapy, despite an earlier ESR1 mutation–targeted approval and after-hours stock weakness. The broader trial that reached more patients failed, while a separate study in ESR1-mutant patients showed a meaningful benefit, underscoring a split outcome for the drug’s potential.

Health· Sep 11, 2026

Facts from Wikidata (CC0).

palbociclib

drug for the treatment of ER-positive and HER2-negative breast cancer developed by Pfizer

0members1here now

Ask Genius Site

Site Journal

Feed Discussions About

Sort by

Content type

Latest palbociclib news and discussion

Sort by

Content type

Ppalbociclib· Health · 10 sources · Sep 11, 2026Story

AstraZeneca Breast Cancer Trial Misses Key Goal

Health· Sep 11, 2026

Facts from Wikidata (CC0).

palbociclib across IJR

Ask Genius by OpenServe about palbociclib Create in Studio Build a game Watch videos

About palbociclib

Palbociclib, sold under the brand name Ibrance among others, is an anti-cancer medication used for the treatment of HR-positive and HER2-negative breast cancer. It was developed by Pfizer. It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6. Palbociclib was the first CDK4/6 inhibitor to be approved as a cancer therapy.

members

here now

Coverage spread L20 / C30 / R50

Everything about palbociclib →

Live room · 1 here

Be the first in the room — members see you arrive.

Join the room

palbociclib across IJR

Ask Genius by OpenServe about palbociclib Create in Studio Build a game Watch videos